Literature DB >> 10372125

Engraftment and multilineage expression of human bone marrow CD34- cells in vivo.

E D Zanjani1, G Almeida-Porada, A G Livingston, C D Porada, M Ogawa.   

Abstract

The fetal sheep competitive engraftment model of human hematopoietic stem cells (HSC) was used to evaluate the in vivo engraftment potential of human bone marrow CD34- Lin- cells. Transplantation of CD34- Lin- cells into primary hosts resulted in the long-term (> 1 year) engraftment and multilineage donor cell/progenitor expression with production of significant numbers of CD34+ cells. Secondary transplantation and limiting dilution studies confirmed the presence in human CD34- fraction of HSC with in vivo long-term engraftment and multilineage differentiation potentials.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10372125     DOI： 10.1111/j.1749-6632.1999.tb08467.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  10 in total

1.  Human placenta and chorion: potential additional sources of hematopoietic stem cells for transplantation.

Authors:  Alicia Bárcena; Marcus O Muench; Mirhan Kapidzic; Matthew Gormley; Gabriel A Goldfien; Susan J Fisher
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

Review 2.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

3.  CD34-negative hematopoietic stem cells show distinct expression profiles of homing molecules that limit engraftment in mice and sheep.

Authors:  Tomoyuki Abe; Yoshikazu Matsuoka; Yoshikazu Nagao; Yoshiaki Sonoda; Yutaka Hanazono
Journal:  Int J Hematol       Date:  2017-07-07       Impact factor: 2.490

Review 4.  Reviewing and updating the major molecular markers for stem cells.

Authors:  Raquel Calloni; Elvira Alicia Aparicio Cordero; João Antonio Pêgas Henriques; Diego Bonatto
Journal:  Stem Cells Dev       Date:  2013-01-22       Impact factor: 3.272

5.  RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element.

Authors:  Elena Levantini; Sanghoon Lee; Hanna S Radomska; Christopher J Hetherington; Meritxell Alberich-Jorda; Giovanni Amabile; Pu Zhang; David A Gonzalez; Junyan Zhang; Daniela S Basseres; Nicola K Wilson; Steffen Koschmieder; Gang Huang; Dong-Er Zhang; Alexander K Ebralidze; Constanze Bonifer; Yutaka Okuno; Bertie Gottgens; Daniel G Tenen
Journal:  EMBO J       Date:  2011-08-26       Impact factor: 11.598

6.  Gene expression profile of murine long-term reconstituting vs. short-term reconstituting hematopoietic stem cells.

Authors:  Jiang F Zhong; Yi Zhao; Susan Sutton; Andrew Su; Yuxia Zhan; Lunjian Zhu; Chunli Yan; Tim Gallaher; Patrick B Johnston; W French Anderson; Michael P Cooke
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-04       Impact factor: 11.205

Review 7.  Contribution of human hematopoietic stem cells to liver repair.

Authors:  Ping Zhou; Louisa Wirthlin; Jeannine McGee; Geralyn Annett; Jan Nolta
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

8.  A paradigm for virus-host coevolution: sequential counter-adaptations between endogenous and exogenous retroviruses.

Authors:  Frederick Arnaud; Marco Caporale; Mariana Varela; Roman Biek; Bernardo Chessa; Alberto Alberti; Matthew Golder; Manuela Mura; Ya-Ping Zhang; Li Yu; Filipe Pereira; James C Demartini; Kreg Leymaster; Thomas E Spencer; Massimo Palmarini
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

9.  Fanconi anemia genes are highly expressed in primitive CD34+ hematopoietic cells.

Authors:  Michel Aubé; Matthieu Lafrance; Isabelle Brodeur; Marie-Chantal Delisle; Madeleine Carreau
Journal:  BMC Blood Disord       Date:  2003-06-16

Review 10.  In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application.

Authors:  Graça Almeida-Porada; Anthony Atala; Christopher D Porada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.